TORII PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,760 JPY | -0.53% |
|
+2.59% | +5.77% |
| Feb. 13 | LIM Advisors Partially Withdraws Shareholder Proposal | CI |
| Feb. 09 | Torii Pharmaceuticals Opposes Shareholder Proposal | CI |
| Sales 2024 * | 57.8B 373M | Sales 2025 * | 61.22B 395M | Capitalization | 106B 685M |
|---|---|---|---|---|---|
| Net income 2024 * | 4.88B 31.51M | Net income 2025 * | 5.65B 36.47M | EV / Sales 2024 * | 1.84 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.73 x |
| P/E ratio 2024 * |
21.7
x | P/E ratio 2025 * |
18.8
x | Employees | 583 |
| Yield 2024 * |
3.17% | Yield 2025 * |
3.17% | Free-Float | 42.17% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.53% | ||
| 1 week | +2.59% | ||
| Current month | -8.18% | ||
| 1 month | -6.23% | ||
| 6 months | +1.21% | ||
| Current year | +5.77% |
1 week
3 645.00
3 820.00
1 month
3 645.004 175.00
Current year
3 540.004 370.00
1 year
3 275.004 370.00
3 years
2 322.004 370.00
5 years
2 101.004 370.00
10 years
1 981.004 370.00
| Managers | Title | Age | Since |
|---|---|---|---|
Goichi Matsuda
PSD | President | 57 | 17-02-28 |
| Director of Finance/CFO | - | - | |
Megumi Kajiwara
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Corporate Officer/Principal | 60 | 87-03-31 | |
Masao Torikai
BRD | Director/Board Member | 61 | 10-05-31 |
Masaki Sunami
PRN | Corporate Officer/Principal | 65 | 14-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.12% | 15 M€ | +7.30% | ||
| 0.05% | 2 M€ | -.--% | ||
| 0.02% | 7 M€ | -.--% | - | |
| 0.01% | 18 M€ | +16.15% | - | |
| 0.01% | 20,721 M€ | +14.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 3,760 | -0.53% | 18 900 |
| 24-04-23 | 3,780 | +0.40% | 14,900 |
| 24-04-22 | 3,765 | +2.03% | 20,100 |
| 24-04-19 | 3,690 | -2.25% | 22,300 |
| 24-04-18 | 3,775 | +3.00% | 44,900 |
Delayed Quote Japan Exchange, April 24, 2024 at 02:00 am EDT
More quotes
TORII PHARMACEUTICAL CO., LTD. is mainly engaged in the manufacture and sale of pharmaceutical products. The Companyâs main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Companyâs main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.77% | 686M | |
| +27.92% | 672B | |
| +27.00% | 570B | |
| -4.59% | 360B | |
| +16.38% | 321B | |
| +9.39% | 300B | |
| +7.44% | 217B | |
| +6.37% | 199B | |
| -8.92% | 204B | |
| -8.58% | 149B |
- Stock Market
- Equities
- 4551 Stock
